Table III.
Radiotherapy utilization, including external beam and skeletal target (n=236).
| Courses of radiotherapy, n (%) | ||||||
|---|---|---|---|---|---|---|
| Parameter | 0 | 1 | 3 | ≥3 | P-value | Median target volumesa |
| Age, years | ||||||
| <75 | 21 (20) | 42 (40) | 14 (13) | 28 (27) | 2.0 | |
| ≥75 | 48 (37) | 59 (45) | 20 (15) | 4 (3) | <0.0001 | 1.0 |
| Initial symptom | ||||||
| MSCC/PF | 0 (0) | 5 (42) | 3 (25) | 4 (33) | 2.0 | |
| Other | 69 (31) | 96 (43) | 31 (14) | 28 (13) | 0.0100 | 1.0 |
| MSCC/PFb | ||||||
| Not present | 67 (40) | 65 (39) | 22 (13) | 14 (8) | 1.0 | |
| Present | 2 (3) | 36 (53) | 12 (18) | 18 (26) | <0.0001 | 2.5 |
| Chemotherapyc | ||||||
| No chemotherapy | 57 (38) | 64 (43) | 22 (15) | 6 (4) | 1.0 | |
| One line only | 6 (13) | 21 (46) | 8 (17) | 11 (24) | 2.0 | |
| Two lines | 5 (19) | 10 (37) | 4 (15) | 8 (30) | 2.0 | |
| Three lines | 1 (7) | 6 (43) | 0 (0) | 7 (50) | 0.0001 | 2.5 |
| Overall systemic therapyd | ||||||
| None | 51 (54) | 34 (36) | 10 (11) | 0 (0) | 0 | |
| Bone-targeting | 6 (11) | 31 (56) | 12 (22) | 6 (11) | 2.0 | |
| Chemotherapy | 8 (50) | 5 (31) | 1 (6) | 2 (13) | 0.5 | |
| Both | 4 (6) | 31 (44) | 11 (16) | 24 (34) | 0.0001 | 2.0 |
| Survival, months | ||||||
| <12 | 30 (42) | 32 (45) | 8 (11) | 1 (1) | 1.0 | |
| 12–24 | 20 (28) | 33 (46) | 10 (14) | 9 (13) | 1.0 | |
| 24–36 | 12 (31) | 12 (31) | 6 (15) | 9 (23) | 2.0 | |
| 36–48 | 4 (17) | 10 (42) | 4 (17) | 6 (25) | 2.0 | |
| >48 | 3 (10) | 14 (47) | 6 (20) | 7 (23) | 0.0100 | 2.0 |
a
All courses combined.
b
Between diagnosis of bone metastases and death.
c
Includes cytotoxic chemotherapy, abiraterone and enzalutamide.
d
Includes cytotoxic chemotherapy, abiraterone, enzalutamide, bisphosphonates and denosumab. MSCC/PF, metastatic spinal cord compression/pathological fracture.